By means of functional genomics analysis, we recently described the mRNA expression profiles of various genes involved in the neuroinflammatory response in the brains of subjects with late-onset Alzheimer Disease (LOAD). Some of these genes, namely interleukin (IL)-1b and IL-6, showed distinct expression profiles with peak expression during the first stages of the disease and control-like levels at later stages. IL-1b and IL-6 genes are modulated by DNA methylation in different chronic and degenerative diseases; it is also well known that LOAD may have an epigenetic basis. Indeed, we and others have previously reported gene-specific DNA methylation alterations in LOAD and in related animal models. Based on these data, we studied the DNA methylation profiles, at single cytosine resolution, of IL-1b and IL-6 5'-flanking region by bisulphite modification in the cortex of healthy controls and LOAD patients at 2 different disease stages: Braak I-II/A and Braak V-VI/C. Our analysis provides evidence that neuroinflammation in LOAD is associated with (and possibly mediated by) epigenetic modifications.
INTRODUCTION
Late-onset Alzheimer disease (LOAD) is one of the most prevalent neurodegenerative diseases. It is characterized clinically by progressive cognitive impairment and dementia and neuropathologically by the presence of extracellular deposits of b-amyloid protein, thus forming senile plaques, intracellular deposits of hyper-phosphorylated tau protein in neurofibrillary tangles and dystrophic neurites leading to neuronal degeneration and neuron loss (1) . Unlike the familial (monogenic) forms of the disease, which appear at an early age (commonly designated as early-onset Alzheimer disease or familial Alzheimer disease) and are linked to mutations in APP (b-amyloid precursor protein), PSEN1 and PSEN2 (presenilin 1 and 2, respectively), several risk factors have been associated with LOAD. In this complex scenario, LOAD may be modulated by epigenetic mechanisms; indeed, differential DNA methylation of specific gene promoters has been associated with different molecular mechanisms involved in LOAD (2) .
Neuroinflammation is a common event in LOAD (3) (4) (5) (6) . We recently assessed the mRNA expression profile of cytokines and mediators of the immune system in the human frontal cortex area 8, of middle-aged (MA) individuals and patients with LOAD at stages I-II/0(A), III-IV/A-B, and V-VI/ C (7). Altered expression of several components was observed to be stage-dependent. In particular, mRNA expression of IL1b and IL-6 showed a peak during the first stages I-II/0(A), followed by return to control-like levels at advanced stages V-VI/C of the disease (7) .
It has been recently demonstrated that certain proinflammatory cytokines, including IL-1b and IL-6, are epigenetically regulated by differential DNA methylation of their promoters in certain unrelated conditions as hypoxia, small cell lung cancer and arthritis (8) (9) (10) . On the other hand, differential DNA methylation of IL-6 seems to participate in the modulation of cognition under specific settings (11) . We recently reported IL-1b promoter-specific hypomethylation, associated with IL-1b mRNA overexpression in the brains of patients with tuberous sclerosis complex, both in tuberal and perituberal tissues compared to control samples (12) .
In this study, we examined the methylation status of 3 genes (IL-1b, IL-6 and C3ar1) in the same series of cases analyzed in our seminal study (7) . The genes were selected on the basis of their characteristic expression profiles during early and late stages of the disease. The analysis of the methylation profile of the 5 0 -flanking region of the selected genes was performed by bisulphite assay, taking advantage of a recent study that demonstrated the unbiased efficiency of non-CpG-methylation-insensitive primers (MIPs) by assessing both CpG and non-CpG DNA methylation (13) .
MATERIALS AND METHODS

Patients
Human brain tissue samples from frontal cortex (n ¼ 15 per group) were obtained from healthy MA subjects and LOAD patients (Braak stages I-II/A and V-VI/C), from the Institute of Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank, Barcelona, Spain) and Clinic Hospital-IDIBAPS Biobank (Barcelona, Spain), following the guidelines of Spanish legislation and of the local ethics committee. The samples were frozen blocks of the frontal cortex area 8; other details on the tissue collection and the characterization of control and LOAD cases have been reported (7) . Characteristics of the MA and LOAD subjects are summarized in Table 1 .
DNA Methylation Study by Bisulphite Modification and Genomic Sequencing
DNA was extracted from tissues using the DNeasy Blood and Tissue Kit (Cat. no. 69504, Lot no. 136269927) and the Qiacube instrument (Qiagen, Milan, Italy).
Bisulphite analysis of IL-1b, IL-6 and C3ar1 promoter methylation was performed as previously described in (13) using the EpiTect Bisulphite kit (Qiagen, Cat. no. 59104, Lot no.148047988). Fifty ng of bisulphite-treated genomic DNA was amplified using the specific PCR primers listed in Table 2 and PCR products obtained were cloned using the PCR Plus Cloning Kit (Qiagen, Cat. no. 231224, Lot no.145016955). After white/blue screening on LB-agar plates, at least 10 positive clones were analyzed per experimental condition using M13 primers for sequencing. Sequencing reactions of purified plasmid DNA were performed. Clones were sequenced by the cycle sequencing method (in service by PRIMM, Milan, Italy).
Modified cytosine residues were recognized through comparison with the original DNA sequence and methylation status of each single cytosine in every sequenced clone and reported as 1/0 value in an Excel spreadsheet (methylated: 1; unmethylated: 0). For each experimental sample we obtained the methylation percentage of each single cytosine by calculating the number of methylated cytosines divided by the number of clones sequenced per 100 no methylC no sequenced clones Â 100
We then calculated the average methylation percentage over the tissue samples for each experimental condition.
GenBank accession numbers, primer names, sequences and position and expected products of the MIPs used for bisulphite analysis are presented in Table 2 . These primers allowed assessing methylation status of plus (5 0 ->3 0 ) DNA strand. We also used different bisulphite modification assays as random controls in samples characterized by low and high (CpG and non-CpG) methylation to ensure that cytosine conversion was complete (13) . In all of these cases, the observed methylation patterns were similar. As negative controls of bisulphite modifications, we used unmethylated purified PCR products of gene promoters obtained from genomic DNA as template with the same MIPs primers used for bisulphite PCR; these purified PCR products were also methylated in vitro with SssI methylase (New England Biolabs, Beverly, MA), which methylates only cytosines in CpG dinucleotides to be used as positive controls.
Statistical Analysis
Stat view 5.0 (SAS Institute, Milan, Italy) statistical software was used. Mann-Whitney non-parametric tests were applied because the experimental method (sequencing of at least 10 clones for each experimental replicate) results in percent values (methylation %) for many cytosines (non-correlated values) in each sample.
Ethical Issues
Work on human subjects: the postmortem brains used in the present study were obtained from the Institute of Neuropathology and Brain Bank (HUB-ICO-IDIBELL Biobank) following the guidelines of the Declaration of Helsinki, and according to the Spanish and Catalonian Autonomous regulations on this matter, and with the approval of the local Ethics Committee of the Bellvitge University Hospital. 
RESULTS
DNA methylation status of CpG (highlighted in grey boxes) and non-CpG moieties in the 5'-flanking region of the IL-1b, IL-6 and C3ar1 genes was determined by bisulphite treatment of genomic DNA purified from cortical tissue (frontal cortex) of MA cases and subjects with LOAD at stages I-II/ A and V-VI/C (Fig. 1) .
For IL-1b, our previous study showed the following expression values: 1.15 6 0.09 in MA; 5.19 6 1.71 at stage A; and 3.58 6 0.79 at stage V-VI/C (1-way ANOVA with post hoc Tukey range test for multiple comparisons, p values between 0.5 and 0.01) (7). The present findings revealed significant hypomethylation (U ¼ 16.00, p < 0.001) in DNA IL-1b promoter at stage I-II/A vs MA individuals. However, methylation in DNA IL-1b promoter returned to nearly MA values at stage V-VI/C (Fig. 1A-C) . Differences were mainly observed at non-CpG sites, whereas the 2 CpG sites (cytosines 1006 and 1049) of the studied region maintained high methylation levels in MA and LOAD cases.
The IL-6 mRNA expression values in the study were as follows: 1.22 6 0.18 in MA; 3.00 6 0.76 at stage I-II; and 2.13 6 0.39 at stage V-VI/C (p values < 0.05) (7). In the present study, the methylation profile of the 5'-flanking region of IL-6 gene showed high methylation levels in MA cases with progressive hypomethylation at stages I-II/A and stages V-VI/C (U ¼ 16.00, p < 0.005 for both stages vs. MA and for stages V-VI/C vs I-II/A) (Fig. 1D-F) . Progressive demethylation was noticed both in the 5 CpG (cytosines 1457, 1472, 1509, 1522, and 1566) and the non-CpG moieties present in the investigated region.
Finally, C3ar1 mRNA expression values in the previous study were as follows: 1.29 6 0.25 in MA; 2.67 6 0.41 at stages I-II/A and 2.89 6 0.42 at stages V-VI/C (p values 0.01) (7). Unlike the first 2 genes, bisulphite analysis revealed that C3ar1 methylation profile is high in MA and LOAD at 5 CpG (cytosines 406, 425, 522, 543, and 665) and non-CpG sites in the investigated region (Fig. 1G-I) .
These results are schematically depicted in Table 3 .
DISCUSSION
The 3 genes assessed in the present work were chosen for their particular mRNA expression profiles in AD with the progression of the disease; the expression levels of IL-1b and IL-6 mRNAs increased during the first stages of the disease and decrease thereafter, whereas the expression levels of C3ar1 mRNA increased with disease progression (7). However, methylation levels of the investigated DNA promoter regions varied from one gene to another, and do not always correlate with the expected expression levels of their corresponding mRNAs. In summary, IL-1b methylation decreases at first stages of AD and increases to MA values at advanced stages; IL-6 methylation progressively decreases with disease progression; and C3ar1 methylation is similar in MA and LOAD cases.
Variable results cannot be attributed to artifacts related to postmortem delay because DNA methylation is well preserved in the postmortem human brain (14) . One possibility is that IL-1b, IL-6 and C3ar1 are expressed in different cell types with variable gene regulation profiles. However, the same tissues were used for mRNA and methylation studies. Only IL1b shows a pattern compatible with the expected relation of "low DNA methylation/high mRNA expression'. It is clear that this is not the profile expected for IL-6 because marked demethylation at advanced stages does not correlate with mRNA expression levels. Yet the most dramatic paradigm is represented by C3ar1 for which no correlation between DNA methylation and mRNA expression has been identified.
On the other hand, epigenetic modulation in LOAD is not necessarily observed at the genomic level. Rather, it is a sequence-specific modulation of specific genes. Our previous studies on PSEN1 gene in AD model mice showed that modulation of one-carbon metabolism (and hence of methylation) can induce gene-specific methylation alterations, which are responsible for altered gene expression that affects several ADlike features (15) .
A relevant observation of our present work is that the alteration of DNA methylation of specific genes deregulated in LOAD is not limited to CpG sites but also involves several non-CpG cytosines. Non-CpG methylation has been so far considered as limited to embryonic tissues or stem cells, although recent studies stress the hypothesis that the extent of non-CpG methylation is higher than expected in terminally differentiated tissues. We recently demonstrated that this inconsistency of data is largely due to a bias in the design of the PCR primers used after bisulphite modification (13) . Using MIPs, it was possible to demonstrate discrete non-CpG methylation, which is dynamically changing in correlation with gene expression, as previously demonstrated in tuberous sclerosis complex samples (12) .
Although previous studies have pointed out age-related IL-1b hypomethylation (11), both healthy MA and LOAD patients from which the brain tissue was obtained were agematched (Table 1) , clearly suggesting that the variations observed in our study are age-independent. Moreover, it is not possible to compare the 2 studies because in the previous paper (11) only CpG methylation at the level of the structural region of the gene (not in the promoter region) was studied.
Although disclosing the relevance of DNA methylation in cytokine regulation in the human brain, the present findings also initiate new questions that deserve further investigation. One major point will be to clarify what cell type is responsible for the observed changes in DNA methylation and/or gene expression because in the cortex, microglia (which are mainly responsible for IL-1b and C3ar1 production) are a minority population. Cell population-specific epigenetic studies would help to clarify on one hand whether neurons and astrocytes DNA could mask epigenetic changes occurring in microglial cells or, on the other hand, whether the observed methylation profiles are due to changes in the cell population composition due to selective cell death associated to the progression of the pathologic processes. Finally, other epigenetic modification (ie histone modification or miRNAs) could be responsible for gene regulation in place or in addition to DNA methylation.
Together, the present findings point to the necessity of studying whole methylation sites in DNA promoters and flanking regions and show for the first time that the expression of specific cytokine genes is associated with differential DNA AD, Alzheimer disease; I-II/A, IV-VI/C, Braak stages; seminal study (13) . MA, middle-aged controls; AD, Alzheimer disease; I-II/A, IV-VI/C, Braak stages.
